The relative AT(1) and AT(2) binding affinities of l-5-yl)biphenyl-4-y
l)methyl]quinazolin-4-(3H)-ones can be manipulated by changing the sub
stitution at positions C-2 and N-6 of the quinazolinone nucleus. L-161
,638 was identified as a potent orally bioavailable and AT(2) selectiv
e angiotensin II binding inhibitor.